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The master regulatory transcription factor GATA-2
triggers hematopoietic stem and progenitor cell gen-
eration. GATA2 haploinsufficiency is implicated in
myelodysplastic syndrome (MDS) and acute myeloid
leukemia (AML), and GATA2 overexpression por-
tends a poor prognosis for AML. However, the con-
stituents of the GATA-2-dependent genetic network
mediating pathogenesis are unknown. We described
a p38-dependent mechanism that phosphorylates
GATA-2 and increases GATA-2 target gene activa-
tion. We demonstrate that this mechanism es-
tablishes a growth-promoting chemokine/cytokine
circuit in AML cells. p38/ERK-dependent GATA-2
phosphorylation facilitated positive autoregulation
of GATA2 transcription and expression of target
genes, including IL1B and CXCL2. IL-1b and CXCL2
enhanced GATA-2 phosphorylation, which increased
GATA-2-mediated transcriptional activation. p38/
ERK-GATA-2 stimulated AML cell proliferation via
CXCL2 induction. As GATA2 mRNA correlated with
IL1B andCXCL2mRNAs in AML-M5 and high expres-
sion of thesegenes predictedpoor prognosis of cyto-
genetically normal AML,wepropose that the circuit is
functionally important in specific AML contexts.
INTRODUCTION
The heterogeneous malignancy acute myeloid leukemia (AML)
is characterized by aberrant myeloid cell proliferation and differ-
entiation (Coombs et al., 2016). AML prognosis in geriatric pa-
tients has a 5-year survival of 5%–10% (Klepin et al., 2014),
and 30%–40% of pediatric patients do not experience long-
term survival (Zwaan et al., 2015). Whereas defects in signaling
and gene expression mechanisms controlling hematopoiesis
can cause AML, many questions remain regarding the signals,
factors, and circuits.
RAS and KIT mutations, which can be mutually exclusive or
co-occur in AML patients, yield aberrant signaling molecules
that stimulate AML cell proliferation (Boissel et al., 2006; Goe-2428 Cell Reports 16, 2428–2441, August 30, 2016 ª 2016 The Autho
This is an open access article under the CC BY-NC-ND license (http://mans et al., 2005). Recently, GATA-2, a master regulator of he-
matopoietic stem and progenitor cell (HSPC) genesis/function
(Tsai et al., 1994), was implicated in AML. Heterozygous
GATA2 mutations cause a primary immunodeficiency (Mono-
MAC) associated with myelodysplastic syndrome (MDS) that
progresses to AML (Dickinson et al., 2011; Hahn et al., 2011;
Hsu et al., 2011; Ostergaard et al., 2011). GATA2 mutations
were detected in 7% of pediatric MDS patients (Wlodarski
et al., 2016). Thesemutations attenuate GATA-2 chromatin bind-
ing, thus disrupting the GATA-2-dependent genetic network
(Katsumura et al., 2014). Heterozygous mutations of a Gata2
intronic enhancer (+9.5 kb), which normally increases Gata2
expression in hemogenic endothelium, hematopoietic stem cells
(HSCs), and myeloid progenitors (Gao et al., 2013; Grass et al.,
2006; Johnson et al., 2012; Sanalkumar et al., 2014), cause
MonoMACwith a phenotype resembling patients with coding re-
gion mutations (Hsu et al., 2013; Johnson et al., 2012).
A distinct mechanism deregulates GATA2 in poor prognosis
3q21-q26 AML, which constitutes2% of AML. An inversion re-
positions a GATA-2-binding GATA2 cis element (77 kb) (Grass
et al., 2006) to a region upstream of the distant oncogene EVI1,
increasing EVI1 and decreasing GATA2 expression (Gro¨schel
et al., 2014; Yamazaki et al., 2014). Deletion of the 77 kb site
reduces Gata2 expression in myeloid progenitors, confers a dif-
ferentiation blockade, and is embryonic lethal (Johnson et al.,
2015). These results suggest that reduced GATA-2 expression
in progenitors and ectopic EVI1 expression underlie leukemo-
genesis. Epigenetic alterations can decreaseGATA2 expression
in normal karyotype AML (Celton et al., 2014). While decreased
GATA2 expression is linked to MDS/AML, increased GATA2
expression correlates with poor prognosis adult and pediatric
AML (Luesink et al., 2012; Vicente et al., 2012). Gain-of-function
mutations in chronic myeloid leukemia (Zhang et al., 2008) and
GATA-2 overexpression in murine bonemarrow suppress hema-
topoiesis (Persons et al., 1999). GATA-2 activity must be main-
tained within a physiological window, as decreases or increases
disrupt theGATA-2-dependent genetic network, initiating or pro-
moting leukemogenesis. The vital constituents of the network
and their circuits are largely unknown.
Ras-p38 signaling stimulates GATA-2 S192 phosphorylation,
which promotes multi-site GATA-2 phosphorylation and en-
hances GATA-2-mediated transcriptional activation in pro-
erythroblast and endothelial cells (Katsumura et al., 2014).r(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)
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GATA-2 and oncogenic Ras cooperatively promote non-small-
cell lung cancer and colon cancer (Kumar et al., 2012; Shen
et al., 2014; Steckel et al., 2012). NRAS, KRAS, and HRAS
mutations occur in 10%, 5%, and 5% of AML patients (Ward
et al., 2012). Considering that Ras-p38 signaling stimulates
GATA-2 activity, we asked whether the Ras-GATA-2 axis
functions in AML cells. p38/ERK functions through a GATA-2
docking site for ERK FXF (DEF) motif (Jacobs et al., 1999) to
phosphorylate GATA-2 in AML cells, and DEF motifs have not
been implicated in GATA factor mechanisms. This mechanism
enhances GATA-2-mediated activation of select target genes,
including genes implicated in leukemogenesis (GATA2, TAL1,
IL1B, and CXCL2). These results revealed a positive-feedback
circuit in which Ras-p38/ERK-GATA-2 upregulate CXCL2 ex-
pression, CXCL2 stimulates AML (Kasumi-1) cell prolifera-
tion, and CXCL2 acts on GATA-2-expressing cells to stimulate
the signal-dependent GATA-2 mechanism. Coupled with in-
sights from AML patient data and the poor prognosis of AML
highly expressing the CXCL2 receptor CXCR2 (Schinke et al.,
2015), the p38/ERK-GATA-2 axis may inform AML therapeutics
development.
RESULTS
Ras-p38/ERK- and GATA-2 DEFMotif-Mediated GATA-2
Phosphorylation and Transcriptional Activation in AML
Cells
Given that GATA-2 levels/activity must be tightly controlled to
ensure normal hematopoiesis, we tested whether the p38-
GATA-2 pathway functions in AML cells. We analyzed GATA-2
phosphorylation in Kasumi-1 cells harboring KIT and RUNX1
mutations, which were derived from a pediatric M2 stage
AML patient (Asou et al., 1991). Previously, we described
GATA-2 phosphorylation sites that create a slow mobility
GATA-2 isoform detected by SDS-PAGE. We demonstrated
that l-phosphatase converts phosphorylated GATA-2 to aFigure 1. Ras-p38/ERK- and GATA-2 DEF Motif-Mediated GATA-2 Pho
(A) Total Kasumi-1 cell protein was incubated with or without l-phosphatase and
(B) Left: western blot analysis of endogenous GATA-2 in Kasumi-1 cells with or
protein levels is shown. The ratio of intensities of the upper to lower bands from
(C) Left: western blot analysis of MAP kinases and wild-type andmutant proteins tr
GATA-2 was detected with anti-HA antibody. Right: densitometric analysis of rela
from HA-GATA-2-expressing Kasumi-1 cells was designated as 1 (n = 3, mean ±
(D) Top: western blot analysis of substrates of MAP kinases, GATA-2, and Ras pro
MAP kinase inhibitors. Expressed GATA-2 was detected with anti-HA antibod
specificities. Bottom: densitometric analysis of relative protein levels is shown. T
Kasumi-1 cells was designated as 1 (n = 3, mean ± SE, *p < 0.05 and **p < 0.01
(E) Left: western blot analysis of MAP kinases, substrates of MAP kinases, an
constitutively active MEK1 or p38. Expressed GATA-2 protein was detected wi
shown. The ratio of intensities of the upper to lower bands from GATA-2-expres
(F) DEF motif in GATA-2 is shown.
(G) Left: western blot analysis of MAP kinases and wild-type andmutant proteins t
GATA-2 was detected with anti-HA antibody. Right: densitometric analysis of rela
HA-GATA-2-expressing Kasumi-1 cells was designated as 1 (n = 3, mean ± SE,
(H) Total protein from Kasumi-1 cells expressing GATA-2 proteins was incubated w
anti-HA antibody.
(I) Left: western blot analysis of HA-GATA-2 and HA-GATA-2DDEF transiently exp
mRNA levels in MAE cells transiently expressing HA-GATA-2 and HA-GATA-2DD
See also Figure S1.
2430 Cell Reports 16, 2428–2441, August 30, 2016dephosphorylated, fast-migrating isoform (Katsumura et al.,
2014). In Kasumi-1 cells, l-phosphatase decreased the slow
mobility phosphorylated isoform of endogenous GATA-2 (Fig-
ure 1A). Identical results were obtained with Kasumi-3 cells (Fig-
ure S1A), an AML cell line derived from adult M0 AML with t (3; 7)
(q27; q22) and high EVI1 expression (Asou et al., 1996). To deter-
mine the influence of MAPK signaling on GATA-2 phosphoryla-
tion in AML cells, we expressed constitutively active oncogenic
Ras, Ras(G12V). Ras(G12V) induced the slow mobility isoform
of endogenous (Figure 1B) and expressed GATA-2 (Figures 1C
and S1B). In our prior G1E proerythroblast and HEK293 analyses
(Katsumura et al., 2014), Ras(G12V) stimulated GATA-2 S192
phosphorylation, inducing multi-site phosphorylation, which
yields the slow-migrating isoform. S192A mutation abrogated
Ras(G12V)-induced GATA-2 hyperphosphorylation in Kasumi-1
and Kasumi-3 cells (Figures 1C and S1B).
Distinct MAPKs phosphorylate similar target sequences, and
sequences surrounding the phosphorylated residues (S73,
S119, and S192) are predicted to generate phosphorylation sites
for p38, ERK, and JNK. To determine which MAPK mediates
GATA-2 hyperphosphorylation in AML cells, GATA-2 hyperphos-
phorylation was assessed in SB203580- (p38 MAPK inhibitor),
U0126- (MEK inhibitor), and SP600125- (JNK inhibitor) treated
Kasumi-1 cells. Whereas SB203580 and U0126 suppressed
GATA-2 hyperphosphorylation, SP600125 had no effect (Fig-
ure 1D). Similar results were obtained in Kasumi-3 cells (Fig-
ure S1C). Constitutively active MEK1 and constitutively active
p38a induced GATA-2 hyperphosphorylation (Figure 1E).
GATA-2 contains an FXFP sequence, and these DEFmotifs are
recognized by ERK2 and p38a, but not JNK3 (Jacobs et al., 1999).
ERK2 and p38a have a DEF pocket that binds DEFmotif-contain-
ing substrates (Tzarum et al., 2013). As DEF motifs have not been
characterized in GATA factors and the conserved GATA-2 DEF
motif (lacking in GATA-1) is located 20 amino acids N-terminal
to S192 (Figure 1F), we tested whether it mediates signal-depen-
dent GATA-2 phosphorylation. Mutating the DEF motif (F171Asphorylation in AML Cells
analyzed by western blotting with anti-GATA-2 antibody.
without expression of H-Ras(G12V). Right: densitometric analysis of relative
control Kasumi-1 cells was designated as 1 (n = 3, mean ± SE, *p < 0.05).
ansiently expressed in Kasumi-1 cells with or without H-Ras(G12V). Expressed
tive protein levels is shown. The ratio of intensities of the upper to lower bands
SE, **p < 0.01).
teins transiently expressed in Kasumi-1 cells with or without H-Ras(G12V) and
y. ERK, HSP27, and c-Jun phosphorylation was assessed to test inhibitor
he ratio of intensities of the upper to lower bands from Ras(G12V)-expressing
).
d GATA-2 proteins transiently expressed in Kasumi-1 cells with or without
th anti-HA antibody. Right: densitometric analysis of relative protein levels is
sing Kasumi-1 cells was designated as 1 (n = 3, mean ± SE, **p < 0.01).
ransiently expressed in Kasumi-1 cells with or without H-Ras(G12V). Expressed
tive protein levels is shown. The ratio of intensities of upper to lower bands from
**p < 0.01).
ith or without l-phosphatase. Proteins were analyzed by western blotting with
ressed inMAE cells with or without Ras(G12V). Right: qRT-PCR analysis ofHdc
EF with or without Ras(G12V) is shown (n = 3, mean ± SE, *p < 0.05).
Figure 2. Ras-p38/ERK Enhance GATA-2-Mediated Target Gene Transcription in AML Cells
(A) Top: western blot analysis of endogenous GATA-2 in Kasumi-1 cells stably infected with sh-luc virus or sh-GATA2 virus. Bottom: densitometric analysis of
relative protein levels is shown. The protein expression in Kasumi-1 cells infected with sh-luc virus was designated as 1.
(B) Real-time RT-PCR analysis of GATA2mRNA and transcripts of GATA-2 target genes in Kasumi-1 cells infected with sh-luc virus or sh-GATA2 virus is shown
(n = 5; mean ± SE; *p < 0.05, **p < 0.01, and ***p < 0.001).
(C) ChIP-seq analysis of endogenous GATA-2 occupancy at GATA2, IL1B, and CXCL2 loci in Kasumi-3 cells, TF-1 cells (Mazumdar et al., 2015), and human
CD34-positive hematopoietic cells (Beck et al., 2013) is shown.
(D) Real-time RT-PCR analysis of transcripts of GATA-2 target genes in Kasumi-1 cells treated with 40 mMSB203580 (n = 4, mean ± SE). Samples were harvested
at the designated times.
(E) Western blot analysis of endogenous GATA-2 in Kasumi-1 cells treated with 40 mM SB203580 is shown (n = 5, mean ± SE, *p < 0.05).
(legend continued on next page)
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and F173A) abrogated Ras(G12V)-induced GATA-2 hyperphos-
phorylation (Figure 1G). The DEF mutant exhibited steady-state
phosphorylation, as l-phosphatase reduced its mobility (Fig-
ure 1H); presumably, other kinases can phosphorylate the
mutant. To analyze DEFmotif function, we quantitated the capac-
ity of wild-type and DEF motif mutant GATA-2 to induce endoge-
nous Hdc mRNA expression in mouse aortic endothelial (MAE)
cells. The MAE assay allows one to uniquely analyze GATA-2-
mediated endogenous gene regulation, and Hdc is a direct
GATA-2 target gene (Katsumura et al., 2014). TheDEFmotifmedi-
ated Ras(G12V)-induced GATA-2 hyperphosphorylation in MAE
cells (Figure 1I), resembling the Kasumi-1 cells. In the presence
of Ras(G12V), the DEF motif mutant was less active than wild-
type GATA-2 (Figure 1I). Thus, p38 and ERK mediate GATA-2
phosphorylation in AML cells, and a DEF motif is required for
signal-dependent GATA-2 function.
To dissect how the p38/ERK-GATA-2 axis functions in AML
cells, we tested whether the signaling mechanism impacts
GATA-2 target gene expression. Previously, we described
GATA-2-regulated stem cell and inflammatory genes in the
mouse aorta, gonad, mesonephros (AGM) region (Gao et al.,
2013) and in human umbilical vein endothelial cells (HUVECs)
(e.g., CXCL2 and IL1B) (Linnemann et al., 2011). To investigate
whether GATA-2 regulates all or a cohort of these genes, we
used Kasumi-1 cells stably infected with retroviruses expressing
control small hairpin RNA (shRNA) targeting luciferase mRNA
(sh-luc) (Kasumi-1/sh-luc cells) or sh-GATA2 (Kasumi-1/sh-G2
cells) (Figure 2A). GATA2 knockdown decreased TAL1 expres-
sion by 50% (p < 0.001) in Kasumi-1 cells, while expression of
KIT, GFI1, and SFPI1, which are also GATA-2 target genes,
was unaffected (Figure 2B).
CXCL2 functions through the CXCR2 receptor, CXCR2 antag-
onism impairs AML cell growth in vivo, and high CXCR2 expres-
sionpredicts poorprognosis of humanAML (Schinke et al., 2015).
IL-1b supports AML cell survival and proliferation (Dubois et al.,
1994; Estrov et al., 1999; Turzanski et al., 2004), and antagonizing
IL-1b signaling inhibits AML cell proliferation (A˚gerstam et al.,
2015; Rambaldi et al., 1991). IL-1b-mediated GM-CSF induction
contributes to this growth effect (Delwel et al., 1989; Bradbury
et al., 1990). Thus, we tested whether GATA-2 regulates CXCL2
and IL1B expression. IL1B and CXCL2 mRNA expression
decreased by 82% and 73%, respectively, in Kasumi-1/sh-G2
cells (Figure 2B). Using a distinct shRNA (sh-G2-2), TAL1,
IL1B, and CXCL2 expression decreased similarly (Figure 2B).
While TAL1 is an established GATA-2 target gene (Lugus et al.,
2007), IL1B and CXCL2 were not known to be direct GATA-2
targets. We tested whether endogenous GATA-2 occupies
IL1B and CXCL2 using chromatin immunoprecipitation seq-
uencing (ChIP-seq) data from Kasumi-3 cells. GATA-2 occupied(F) Real-time RT-PCR analysis of GATA-2 target genes in Kasumi-1 cells treated w
times.
(G) Western blot analysis of endogenous GATA-2 in Kasumi-1 cells treated with
(H) Left: western blot analysis of endogenousGATA-2 andMAP kinase proteins in
and CXCL2 expression in Kasumi-1 cells expressing Ras(G12V) is shown (n = 3,
(I) Real-time RT-PCR analysis of IL1B andCXCL2 expression in Kasumi-1/sh-luc c
and **p < 0.01).
See also Figure S2.
2432 Cell Reports 16, 2428–2441, August 30, 2016chromatin at or near IL1B and CXCL2, as well as the intronic
+9.5 kb GATA2 enhancer (Grass et al., 2006; Johnson et al.,
2012) (Figure 2C). GATA-2 occupied the same sites in human
CD34-positive cells and TF-1 myelo-erythroid cells (Beck et al.,
2013; Mazumdar et al., 2015), and the sites were DNase hyper-
sensitive in CD34-positive cells (Figure 2C). The GATA2 knock-
down did not affect genes flanking IL1B (Figure S2A).
We testedwhether p38 andERK regulateGATA-2 target genes.
SB203580 or U0126 reduced TAL1, IL1B, andCXCL2 expression
in Kasumi-1 cells (Figures 2D, 2F, S2B, and S2C), without
affecting KIT, GFI1, SFPI1, and GAPDH expression (Figures
S2B and S2C). SB203580 and U0126 also decreased GATA2
expression (Figures 2D, 2F, S2B, and S2C), consistent with the
model in which GATA-2 positively autoregulates GATA2 tran-
scription through binding 77 kb and +9.5 kb enhancers (Bres-
nick et al., 2010; Grass et al., 2006). GATA2 primary transcripts
were regulated with kinetics resembling GATA2 mRNA (Figures
2D, right and 2F, right). Whereas SB203580 and U0126 reduced
GATA-2 target gene expression within 6 hr, total GATA-2 protein
was unaffected at this time (Figures 2E and 2G). This analysis sug-
gested that decreased GATA-2 target gene mRNAs did not result
from a rapid decline in total GATA-2 protein. As SB203580 and
U0126 increased the hypophosphorylated isoform (Figures 2E
and 2G), reduced GATA-2 target gene expression was linked to
lower GATA-2 phosphorylation.
To complement the pharmacological analysis, we tested
whether oncogenic Ras-mediated MAPK activation enhanced
GATA-2-dependent transcription. Ras(G12V) expression in
Kasumi-1 cells increased IL1B and CXCL2 mRNA levels in a
GATA-2-dependent manner (Figures 2H and 2I). Whereas
Ras(G12V) induced IL1B expression 12-fold and CXCL2
expression 1.7-fold in control cells, GATA-2 downregulation
decreased the induction to 3.5- and 1.3-fold (Figure 2I). ERK
and p38 activation by the phosphatase inhibitor okadaic acid
induced S192-dependent GATA-2 hyperphosphorylation (Fig-
ure S2D). Okadaic acid increased GATA2, IL1B, TAL1, and
CXCL2 mRNA levels 10-, 40-, 1.5-, and 3-fold, respectively
(Figure S2E). The okadaic acid activity to regulate GATA-2
phosphorylation and induce GATA-2 target genes was attenu-
ated by SB203580, and treatment of cells with both SB203580
and U0126 yielded more inhibition (Figures S2F and S2G). p38
and ERK also regulated GATA-2 target genes in Kasumi-3
cells (Figures S2H and S2I). These data indicate that p38
and ERK increase GATA-2-mediated target gene activation
in AML cells.
We tested whether the Ras-p38/ERK-GATA-2 axis regulates
GATA-2 chromatin occupancy at CXCL2 and IL1B using func-
tionally important GATA2 cis elements as controls. GATA-2
occupied GATA2 77 kb and +9.5 kb enhancers (Figure 3A),ith 20 mMU0126 (n = 4, mean ± SE). Samples were harvested at the designated
20 mM U0126 is shown (n = 5, mean ± SE, *p < 0.05).
Kasumi-1 cells expressing Ras(G12V). Right: real-time RT-PCR analysis of IL1B
mean ± SE, *p < 0.05 and **p < 0.01).
ells or Kasumi-1/sh-G2 cells expressing Ras(G12V) (n = 6, mean ±SE, *p < 0.05
(legend on next page)
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the disruption of which is linked to leukemogenesis (Gro¨schel
et al., 2014; Johnson et al., 2012; Yamazaki et al., 2014).
SB203580 and U0126 decreased GATA-2 occupancy at 77
kb and +9.5 kb sites 75% and 25%, respectively (Figure 3A).
SB203580 and U0126 reduced GATA-2 occupancy at IL1B
and CXCL2 sites identified by ChIP-seq (Figure 3B). Formalde-
hyde-assisted isolation of regulatory elements (FAIRE) analysis
(Sanalkumar et al., 2014) revealed p38 and ERK inhibition
reduced chromatin accessibility at the GATA-2-occupied 77
kb, IL1B, and CXCL2 sites (Figure 3C). In Kasumi-1/sh-G2 cells,
chromatin accessibility was decreased and MAPK inhibitors
did not alter chromatin accessibility (Figure S3A). GATA-2
dephosphorylation preceded (SB203580) or occurred concomi-
tantly (U0126) with decreased GATA-2 occupancy at the77 kb
site (Figures 3D–3G). GATA-2 overexpression attenuated the
SB203580-induced decrease of IL1B and CXCL2 mRNA (Fig-
ure 3H). Thus, the signaling mechanism increased GATA-2 chro-
matin occupancy and GATA-2-mediated activation of select
GATA2 target genes in AML cells. AP-1 and necrosis factor kB
(NF-kB) occupy chromatin near the GATA-2 site at IL1B (Figures
S3B and S3C). Although GATA-2 directly regulates IL-1B and
CXCL2 expression, one cannot rule out the possibility that
GATA-2 functionally interfaces with these factors that can
mediate the induction of inflammatory cytokines.
p38/ERK-GATA-2 Positive-Feedback Circuit Promotes
Kasumi-1 Cell Proliferation
Chemokine/cytokine signaling through cognate receptors can
activate the MAPK pathway. The CXCL2 receptor CXCR2
activates Ras (Knall et al., 1996) and IL-1b activates p38 (Suzuki
et al., 2001). AML cells express CXCR2 and IL1R1 at
levels comparable to control bone marrow cells, and IL1RAP,
which associates with IL1R1, is overexpressed in AML cells
as described (Figure S4; Barreyro et al., 2012). We tested
whether the GATA-2-dependent increase in IL1B and CXCL2
expression promotes IL-1b and CXCL2 signaling in GATA-2-ex-
pressing cells to further increaseGATA-2 activity through a p38/
ERK-dependent mechanism. Recombinant IL-1b or CXCL2
increased endogenous GATA-2 phosphorylation in Kasumi-1
cells (Figures 4A and 4B). While IL-1b activated p38, CXCL2
activated p38 and ERK (Figures 4A and 4B). IL-1b and CXCL2
increased GATA-2 occupancy at GATA2 77 kb and +9.5 kb
sites in Kasumi-1 cells (Figure 4C), and they induced accumula-Figure 3. p38/ERK Signaling Promotes GATA-2 Chromatin Occupancy
(A)Gata2 locus map. Numbers represent distance to mouse 1S transcription start
GATA-2 occupancy in Kasumi-1 cells treated with 40 mMSB203580 or 20 mMU01
GATA-2 antibody) (inset) illustrates GATA-2 expression in representative sample
(B) Quantitative ChIP analysis of GATA-2 occupancy at GATA-2 target genes in K
mean ± SE, *p < 0.05).
(C) Quantitative FAIRE analysis of chromatin accessibility in Kasumi-1 cells treate
and **p < 0.01).
(D) Kinetics of GATA-2 expression and phosphorylation are shown (n = 3, mean
(E) GATA-2 occupancy at the 77 kb site during 40 mM SB203580 treatment is s
(F) Kinetics of GATA-2 protein expression and phosphorylation are shown (n = 3
(G) GATA-2 occupancy at the 77 kb site during 20 mM U0126 treatment is show
(H) Left: rescue assay. Right: qRT-PCR analysis of IL1B and CXCL2 in Kasumi-1
shown (n = 4; mean ± SE; *p < 0.05; PI, preimmune).
See also Figure S3.
2434 Cell Reports 16, 2428–2441, August 30, 2016tion of the slow mobility GATA-2 isoform (Figure 4D) and
increased GATA2 mRNA (Figure 4E) in patient-derived primary
AML cells. p38/ERK-GATA-2-mediated induction of IL1b and
CXCL2, therefore, constitutes a positive-feedback loop in
AML cells.
Target genes of the p38/ERK-GATA-2 axis (GATA2, IL1B, and
CXCL2) are implicated in AML. We tested whether the GATA-2-
dependent chemokine/cytokine circuit impacts AML cell prolif-
eration. Kasumi-1/sh-G2 cells proliferated slower than control
Kasumi-1/sh-luc cells (Figure 5A). Fluorescence-activated cell
sorting (FACS) analysis of Kasumi-1/sh-G2 and Kasumi-1/sh-
luc cell proliferation revealed reduced proliferation of Kasumi-
1/sh-G2 cells (Figures 5B and 5C). Since downregulating
GATA-2 in Kasumi-1 cells reduced IL1B and CXCL2 expression
and the cells proliferated slower, we tested whether IL-1b and
CXCL2 stimulate Kasumi-1 cell proliferation. Human CXCL2,
but not IL-1b, restored Kasumi-1/sh-G2 cell proliferation (Figures
5D and S3A). FACS analysis also revealed CXCL2-mediated
restoration of Kasumi-1/sh-G2 cell proliferation (Figures 5E, 5F,
and S3B). These results support a model in which the p38/
ERK-GATA-2-instigated chemokine/cytokine circuit controls
AML cell proliferation.
p38/ERK-GATA-2 Positive-Feedback Circuit in Human
AML Patients
We tested whether GATA2 mRNA correlates with GATA-2
target gene mRNAs in AML patient samples. Comparison of
the mRNAs of 19,798 genes in AML patient bone marrow
data from The Cancer Genome Atlas (TCGA) (n = 196) (Fig-
ure 6A) revealed correlations among GATA2, IL1B, and
CXCL2 mRNA levels in AML-M5 patients (Figures 6B and
6C). In AML-M5, high GATA2 expression correlates with
poor prognosis (Luesink et al., 2012). IL1B and GATA2
mRNA levels also correlated in M1, M3, and M4 AML patients
(Figure S6A). Similarly, IL1B and CXCL2 mRNA levels also
correlated in M0, M3, and M4 AML (Figure S6A). IL-1b induces
expression of pro-inflammatory genes including chemokines
(Apte and Voronov, 2008). In Kasumi-1 cells, IL-1b induced
CXCL2 expression (Figure 6D), indicating that GATA-2 in-
creases CXCL2 expression directly via transcriptional activa-
tion and indirectly via IL-1b. These results conform to a type
1 coherent feedforward loop. CXCL2 also increased IL1B
mRNA expression (Figure 6D). Analysis of additional GATA-2and Chromatin Remodeling
site. 1G is anotherGATA2 transcription start site. Quantitative ChIP analysis of
26 is shown (n = 4, mean ± SE, *p < 0.05 and **p < 0.01). The western blot (anti-
s used for ChIP.
asumi-1 cells treated with 40 mM SB203580 or 20 mM U0126 is shown (n = 4,
d with 40 mM SB203580 or 20 mMU0126 is shown (n = 4, mean ± SE, *p < 0.05
± SE, *p < 0.05).
hown (n = 3, mean ± SE, *p < 0.05).
, mean ± SE, *p < 0.05).
n (n = 3, mean ± SE, *p < 0.05).
cells expressing GATA-2 or control vector with or without 10 mM SB203580 is
Figure 4. p38/ERK-GATA-2 Axis Establishes
a Chemokine/Cytokine-Dependent Posi-
tive-Feedback Circuit
(A) Left: western blot analysis of endogenous
GATA-2 in Kasumi-1 cells treated with 10 ng/ml
recombinant human IL-1b. The cells were serum-
starved overnight before IL-1b treatment. Right:
densitometric analysis is shown. The ratio of in-
tensities of the upper to lower bands from at
0 min was designated as 1 (n = 3, mean ± SE,
*p < 0.05).
(B) Western blot analysis of endogenous GATA-2
in Kasumi-1 cells treated with 100 ng/ml re-
combinant human CXCL2. Cells were serum-
starved overnight before CXCL2 treatment.
Right: densitometric analysis is shown. The ratio
of intensities of the upper to lower bands at 0 min
was designated as 1 (n = 3, mean ± SE, *p <
0.05).
(C) Quantitative ChIP analysis of GATA-2 occu-
pancy at GATA-2 target genes in Kasumi-1 cells
treated with 10 ng/ml IL-1b or 100 ng/ml CXCL2
(n = 4, mean ± SE). The cells were serum-starved
overnight before treatment with IL-1b or CXCL2
(*p < 0.05).
(D) Left: western blot analysis of endogenous
GATA-2 in primary AML cells treated with 10 ng/ml
recombinant human IL-1b or 100 ng/ml recombi-
nant human CXCL2 for 5 min. The cells were
serum-starved for 90 min before treatment. Right:
densitometric analysis is shown. The ratio of
intensities of the upper to lower bands from
the control sample was designated as 1 (n = 4,
mean ± SE, *p < 0.05).
(E) Real-time RT-PCR analysis of GATA2 mRNA in
primary AML cells treated with 10 ng/ml IL-1b or
100 ng/ml CXCL2 (n = 4, mean ± SE). Primary AML
cells were serum-starved for 90 min and treated
with IL-1b or CXCL2 for 30 min (*p < 0.05).
See also Figure S4.target genes, HDC, RUNX1, and IRF8 (Gao et al., 2013; Katsu-
mura et al., 2014), revealed GATA2 mRNA levels correlated
with HDC and RUNX1 mRNAs, although IRF8 mRNA nega-
tively correlated (Figures S6C–S6F).
Similar GATA2 and CXCL2 mRNA levels correlated in a
distinct human AML patient dataset (Stirewalt et al., 2008). InCell Repthis dataset, GATA2 and CXCL2 mRNA
levels were significantly higher in AML pa-
tients (Figure S7B). Although the samples
were bone marrow and peripheral blood
mononuclear cell derived, correlations
between GATA2 and CXCL2 mRNAs
and between IL1B and CXCL2 mRNAs
were most obvious with bone marrow
(Figure S7C).
We asked whether GATA2, IL1B, and
CXCL2 mRNA levels predict AML prog-
nosis in the publicly available dataset
GEO: GSE12417 (n = 163) (Metzeler
et al., 2008). High CXCL2 expression
correlated with shorter survival (Figure 6E). High GATA2 +
CXCL2 expression and high IL1B and CXCL2 expression corre-
lated with shorter survival in the GEO: GSE12417 cohort (Fig-
ure 6F). GATA2 and CXCL2 mRNA levels correlated, as well as
CXCL2 and IL1B, in M5-AML patients, resembling the TCGA
dataset (Figures 6C and S7D).orts 16, 2428–2441, August 30, 2016 2435
Figure 5. p38/ERK-GATA2 Axis Stimulates
Kasumi-1 Cell Proliferation
(A) Comparison of growth rates of Kasumi-1 cells
stably infected with sh-luc virus or sh-GATA2 virus.
The Kasumi-1/sh-luc cells and Kasumi-1/sh-G2
cells (13 105) were plated, and cells were counted
every second day. Cells were passaged at a den-
sity of 13 105 cells at day 4 (n = 9, mean ± SE, *p <
0.05 and **p < 0.01).
(B) Top: proliferation analysis. Bottom: represen-
tative plots from proliferation analysis of Kasumi-1/
sh-luc cells and Kasumi-1/sh-G2 cells using Cell-
Trace Violet dye are shown. A greater number of
generations indicates the cells underwent more
rounds of cell division.
(C) Left: the average percentage of total cells in
each daughter generation. Each bar represents
three independent experiments from one clonal
line. The western blot inset illustrates the efficacy
of the GATA-2 knockdown (*p < 0.05, **p < 0.01,
and ***p < 0.001). Right: proliferation index of Ka-
sumi-1/sh-luc cells and Kasumi-1/sh-G2 cells is
shown. Each bar represents three independent
experiments from one clonal line (***p < 0.001).
(D) Comparison of the growth rates of Kasumi-1
cells stably infectedwith sh-luc virus or sh-G2 virus
with 100 ng/ml recombinant human CXCL2. The
Kasumi-1/sh-luc cells and Kasumi-1/sh-G2 cells
(1 3 105) were plated, and cells were counted
every second day. Cells were passaged at a den-
sity of 13 105 cells at day 4 (n = 9, mean ± SE, *p <
0.05).
(E) Representative plots from proliferation analysis
of Kasumi-1/sh-luc cells and Kasumi-1/sh-G2 cells
treated with or without 100 ng/ml recombinant
human CXCL2 using CellTrace Violet dye. A
greater number of generations indicates the cells
underwent more rounds of cell division.
(F) Proliferation index of Kasumi-1/sh-luc cells
and Kasumi-1/sh-G2 cells. Cells were cultured
with or without 100 ng/ml CXCL2 for 6 days (n = 3,
mean ± SE, **p < 0.01 and ***p < 0.001).
See also Figure S5.DISCUSSION
Many reports have described inhibitory GATA2 mutations and
elevated GATA2 expression in AML (Bresnick et al., 2012; Dick-
inson et al., 2014; Ganapathi et al., 2015; Spinner et al., 2014;
Wang et al., 2015a; Wlodarski et al., 2016). Herein we described
a GATA-2-chemokine/cytokine circuit that regulates AML cell
proliferation. p38/ERK signaling phosphorylated GATA-2 via a
mechanism requiring a GATA-2 DEF motif. This mechanism
increased GATA-2 chromatin occupancy and expression of
target genes, which constitute a leukemia cell growth-regulatory
circuit. By upregulating IL1B and CXCL2 expression, p38/ERK-
GATA-2 instigates a positive-feedback mechanism that in-
creases AML cell proliferation. Given the clinical correlations
among GATA2, IL1B, and CXCL2 mRNA levels and the correla-
tion between high GATA2/CXCL2 expression and poor prog-
nosis of cytogenetically normal (CN)-AML patients, this circuit
illustrates a mechanistic link between altered GATA-2 levels/ac-2436 Cell Reports 16, 2428–2441, August 30, 2016tivity and AML. It is reasonable to assume that the signal-depen-
dent GATA-2 mechanism impacts a broader repertoire of
functionally important targets that interface with the circuit
described herein.
Although GATA-2 overexpression and GATA-2 loss are
implicated in AML, the mechanisms by which GATA-2 dereg-
ulation contributes to leukemogenesis were unclear. As the
p38/ERK-GATA-2 axis regulates IL1B and CXCL2, both impli-
cated in leukemogenesis, it is attractive to consider the role
of this axis in the link between high GATA-2 expression and
poor-prognosis AML. We propose that GATA-2 stimulates
AML cell proliferation, in part, through CXCL2 and IL1B in-
duction (Figure 7). Can this circuit provide an avenue for
developing AML therapeutics? p38 and ERK signaling are
implicated in AML cell proliferation (Birkenkamp et al.,
1999). p38 inhibition enhances the anti-leukemic activity of
Birinapant, a smac mimetic (Lalaoui et al., 2016). Besides
MAPK inhibitors, HSP90 inhibitors suppress ERK signaling
Figure 6. GATA2, IL1B, and CXCL2 Expression in AML Patients
(A) Heatmap depicts 19,798 genes, based on ranking of the correlation with GATA2 expression.
(B) Heatmap depicts GATA2, CXCL2, and IL1B mRNA correlations.
(C) Scatterplot depicts correlations among GATA2, CXCL2, and IL1B mRNA expression in M5-AML patients.
(legend continued on next page)
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Figure 7. p38/ERK-GATA-2 Axis Function in AML Cells
Ras-p38/ERK signaling increases GATA-2 phosphorylation. GATA-2 phos-
phorylation facilitates GATA-2 chromatin occupancy at GATA-2 target genes.
GATA-2 stimulates GATA2 transcription through positive autoregulation. Loci
are differentially sensitive to the signal-dependent GATA-2mechanism. GATA-
2 upregulates IL1B and CXCL2 expression. These factors activate p38 and
ERK signaling, enhancing GATA-2 activity through a positive-feedback circuit.
GATA-2 increases CXCL2 transcription directly or indirectly (through IL-1b),
which constitutes a type I coherent feedforward loop (FFL). This GATA-2-
chemokine/cytokine circuit is predicted to be an important determinant of AML
cell proliferation.(Zong et al., 2015) and Rac inhibitors suppress p38 signaling
(Zhang et al., 1995). Both inhibitors exert anti-leukemic activ-
ity. CXCR2 is activated by CXCL1, 2, 3, 5, 6, 7, and 8 (Balk-
will, 2004). As CXCR2 antagonism impairs AML cell growth
in vivo (Schinke et al., 2015), it will be instructive to consider
combining interventions upstream (anti-p38 or ERK) and
downstream of GATA-2 (anti-CXCR2), as well as to develop
CXCL2-selective antagonists, to target GATA-2-driven AML.
Interestingly, while Schinke et al. (2015) focused on IL-8,
CXCL2 was the second most highly expressed CXCR2 ligand
in AML patients.(D) Real-time RT-PCR analysis of CXCL2 and IL1BmRNA in Kasumi-1 cells treat
were serum-starved overnight and treated with IL-1b or CXCL2 for 30 min (*p <
(E) Kaplan-Meier plots compare overall survival of patients with high versus low
(F) Kaplan-Meier plots depict overall survival of patients with high versus low GAT
was based on the cohort of 163 patients with CN-AML from the GEO: GSE1241
See also Figures S6 and S7.
2438 Cell Reports 16, 2428–2441, August 30, 2016Consistent with our results, transformed B-lymphocytes from
patients with MonoMAC syndrome have decreased CXCL2
expression (Hsu et al., 2013). Decreased production of GATA-
2-regulated inflammatory mediators may have implications for
MonoMAC immunodeficiency. In this regard, IL1B or CXCR2
mutations increase susceptibility to pathogens (Hang et al.,
2000; Raupach et al., 2006).
The inverse correlation of GATA2 and IRF8 expression
(Figures S6C and S6F) is of considerable interest, since Irf8
mutations cause leukemogenesis in mice (Holtschke et al.,
1996) and decreased IRF8 expression can characterize
AML and MDS patients (Otto et al., 2011; Qian et al.,
2010). GATA-2-regulated leukemogenesis may, therefore,
involve increased production of growth factors and tumor
suppressor downregulation.
In addition to MDS and AML, GATA2 is implicated in non-
small-cell lung cancer, prostate cancer, and glioma (Kumar
et al., 2012; Vidal et al., 2015; Wang et al., 2015b). GATA2
confers chemotherapy resistance of prostate cancer cells
and JNK and AKT are linked to resistance. GATA2 contributes
to glioma cell proliferation in an ERK-dependent manner
(Wang et al., 2015b). Although it is unclear whether GATA-2
is phosphorylated in these cancer cells, given the broad
impact of p38/ERK signaling, the p38/ERK-GATA-2 axis also
may function in these diseases and, therefore, constitute a
foundation for developing therapies for GATA-2-linked solid
tumors.EXPERIMENTAL PROCEDURES
Cell Culture
Kasumi-1 and Kasumi-3 cells were maintained in RPMI 1640 medium con-
taining 1% penicillin-streptomycin and 20% fetal bovine serum (FBS). Ka-
sumi-1 cells stably infected with sh-luc or sh-GATA2 viruses were main-
tained in 2 mg/ml puromycin. MAE cells were maintained in Medium 200
(Gibco/Invitrogen) containing Low Serum Growth Supplement (Gibco/Invi-
trogen) and 1% penicillin-streptomycin. Cells were transfected with the
Nucleofector II.
Real-Time RT-PCR
Total RNA was purified with TRIzol. The cDNA was synthesized with murine
Moloney leukemia virus reverse transcriptase. PCR product accumulation
was monitored by SYBR green fluorescence.
ChIP
Samples containing 3 3 106 cells were crosslinked with 1% formaldehyde for
10min. Lysates were immunoprecipitated with anti-GATA-2 antibody or rabbit
pre-immune serum. The accession numbers for the ChIP-seq datasets are
GEO: GSE45144 and GSE73207.
FAIRE
Cells were fixed with 1% formaldehyde and sonicated to shear the DNA. Then
10% of the sonicated chromatin was used as the input.ed with 10 ng/ml IL-1b or 100 ng/ml CXCL2 (n = 3, mean ± SE). Kasumi-1 cells
0.05).
GATA2, CXCL2, or IL1B mRNA.
A2/IL1BmRNA, GATA2/CXCL2mRNA, and IL1B/CXCL2mRNA. This analysis
7 dataset (Metzeler et al., 2008).
Protein Analysis
Protein samples from 13 106 cells were resolved by SDS-PAGE and proteins
were detected by western blotting.
Phosphatase Treatment
Total protein was prepared by lysing cells in radio-immunoprecipitation assay
(RIPA) buffer. For phosphatase treatment, proteins were incubated with
l-phosphatase at 30C for 90 min and analyzed by western blotting.
Proliferation Analysis
Cells (13 106) were labeled with 10 mMCellTrace Violet Dye. Then 6 days later,
CellTrace Violet fluorescence intensity was measured.
Patient Sample Analysis
Using clinical data from TCGA for AML, 196 patients were identified for the
analysis. The Spearman correlation coefficient was computed. Clinical data
from GEO: GSE12417, with a cohort of 163 patients with CN-AML, was
used for Kaplan-Meier survival analysis (Metzeler et al., 2008). The accession
numbers for clinical datasets are GEO: GSE1159, GSE9476, and GSE12417.
Statistical Analysis
Statistical significance was determined by paired Student’s t test using web-
based GraphPad (http://www.graphpad.com). Significance of Kaplan-Meier
survival analysis was determined by log-rank test.
ACCESSION NUMBERS
The accession numbers for the ChIP-seq dataset of GATA-2 in Kasumi-3 cells
reported in this paper is GEO: GSE84782.
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